Sonomind SAS raised €20 million in a Series A round for its ultrasound-based neuromodulation platform targeting depression. The company plans to use the funding for clinical trials of its non-invasive device, designed to focus energy to deep brain regions using a custom acoustic lens. The technology targets treatment-resistant depression, a segment with unmet needs where non-pharmacologic, device-led options are increasingly being explored. Sonomind’s funding underscores growing capital appetite for neuromodulation tools that can be deployed without surgery. Data from early trials will likely shape whether ultrasound targeting can compete with existing neuromodulation modalities on efficacy, durability, and usability.